REG - ConvaTec Group PLC - Non-Executive Director Changes

ConvaTecAnnouncement

28/02/2022 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220228:nRSb0288Da&default-theme=true

RNS Number : 0288D  ConvaTec Group PLC  28 February 2022

ConvaTec Group PLC

Non-Executive Directors - Appointment and Resignation

 

Reading, United Kingdom - Monday 28 February 2022

 

ConvaTec Group PLC ("ConvaTec" or "the Company") is pleased to announce the
appointment of Sharon O'Keefe as a Non-Executive Director of the Company with
effect from 1 March 2022.  Sharon will join ConvaTec's Remuneration and
Nomination committees on the same date.

The Company also announces that Rick Anderson, Non-Executive Director, is
stepping down from the Board with effect from 3 March 2022.  Rick has made a
significant and valuable contribution to ConvaTec since 2016 for which the
Board is immensely grateful.  Rick is also Chairman and MD of Revival
Healthcare Capital, a role which has recently expanded, and this has led to
his reluctant decision to step down from the Board of ConvaTec.

Sharon O'Keefe

From 2011 to 2020, Sharon was President and Chief Operating Officer of U
Chicago Medicine, a US nationally ranked medical centre with a network of
physicians and speciality clinics with 10,000 employees and operating revenue
in excess of $2 billion.

Sharon has over 40 years of healthcare and executive experience, with
particular focus on quality, efficiency and innovation to create high
performance healthcare organisations.

Sharon is a Non-Executive Director of Adtalem Global Education, a $1.1 billion
global educational services company and of Vocera Communications, a $200
million healthcare technology company. She was previously a Non-Executive
Director of Aviv REIT, a healthcare real estate investment trust that was
acquired by Omega Healthcare Investors in 2015.

 

Sharon has an M.S. in Nursing Administration from the Loyola University of
Chicago, and a B.S. in Nursing from the Northern Illinois University.

John McAdam, Chairman of ConvaTec, commented:

"I am delighted to welcome Sharon to our Board.  She has extensive
executive-level experience in medical centre environments with deep insight
into patient care quality, engagement and innovation.  Sharon brings to the
Board very relevant international, medical and patient-focused experience.
We look forward to Sharon's contribution to our Board discussions."

"The Board is sorry to lose Rick's valuable contribution to the Board's
discussions and his deep insight into the medical device industry. The Board
accepts that Rick is now having to devote more of his time to his role at
Revival Healthcare and we wish Rick every success and happiness for the
future."

This announcement is made in accordance with Listing Rule 9.6.11R (1). No
other information is required to be disclosed in accordance with Listing Rule
9.6.13.

Enquiries:

Analysts and Investors

Kate Postans, Vice President, Investor
Relations
                +44(0)7826 447 807

ir@convatec.com (mailto:ir@convatec.com)

Media

Buchanan: Chris
Lane
                                +44(0)207 466
5000

ConvaTec Group PLC's LEI code is 213800LS272L4FIDOH92

About ConvaTec Group PLC
ConvaTec is a global medical products and technologies company focused on
therapies for the management of chronic conditions, with leading market
positions in advanced wound care, ostomy care, continence and critical care,
and infusion care. Our vision, which encompasses our purpose, is: Pioneering
trusted medical solutions to improve the lives we touch. Our products provide
a range of clinical and economic benefits including infection prevention,
protection of at-risk skin, improved patient outcomes and reduced total cost
of care. To learn more about ConvaTec, please visit www.convatecgroup.com
(http://www.convatecgroup.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUBCPUPPGUR